Embracing Discovery & Innovation
Multimodal - 1st in Class
There is a significant “polypharmacy” crisis in medicine in which multiple medicines are prescribed to treat symptoms of disease. Such a focus on symptoms, as opposed to treating the roots of cell dysfunction, has led to simultaneous use of many “single-mode of action” drugs that often end up competing with one another to promote new imbalances.
The RJX technology is designed to “reboot” the cellular process by knocking on natural doors at the cellular level, but in an entirely new and multi-faceted way from existing drugs and therapies. Multiple modes of action are believed to work together simultaneously to drive cellular restoration at the foundation of each cell, triggering the system of the body towards balance in the process.
Reven believes our “first in class” technology platform will pave the way to shift current prescription paradigms, in some cases mitigating the need for many drugs by focusing on the sources of cellular distress instead.